Zacks Research Issues Positive Estimate for ENSC Earnings

Ensysce Biosciences, Inc. (NASDAQ:ENSC) – Equities researchers at Zacks Research upped their Q3 2026 EPS estimates for Ensysce Biosciences in a research report issued on Tuesday, July 14th. Zacks Research analyst B. Sorensen now anticipates that the company will post earnings per share of $0.09 for the quarter, up from their previous forecast of ($0.49). The consensus estimate for Ensysce Biosciences’ current full-year earnings is ($1.98) per share. Zacks Research also issued estimates for Ensysce Biosciences’ Q4 2026 earnings at ($0.60) EPS and FY2026 earnings at ($1.53) EPS.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Ensysce Biosciences in a report on Tuesday, April 21st. One analyst has rated the stock with a Sell rating, According to MarketBeat, Ensysce Biosciences presently has an average rating of “Sell”.

Ensysce Biosciences Stock Performance

NASDAQ ENSC opened at $0.28 on Friday. Ensysce Biosciences has a one year low of $0.23 and a one year high of $2.75. The company has a market capitalization of $4.26 million, a price-to-earnings ratio of -0.08 and a beta of 0.78. The company’s 50-day simple moving average is $0.29 and its two-hundred day simple moving average is $0.49.

Ensysce Biosciences (NASDAQ:ENSC) last released its quarterly earnings data on Friday, May 15th. The company reported ($0.52) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.73) by $0.21. Ensysce Biosciences had a negative net margin of 250.39% and a negative return on equity of 766.45%. The company had revenue of $0.96 million during the quarter, compared to analysts’ expectations of $1.00 million.

Institutional Trading of Ensysce Biosciences

Institutional investors have recently made changes to their positions in the business. Virtu Financial LLC acquired a new stake in Ensysce Biosciences in the third quarter worth about $34,000. Citadel Advisors LLC acquired a new stake in Ensysce Biosciences in the 3rd quarter worth approximately $34,000. DRW Securities LLC grew its position in Ensysce Biosciences by 42.4% during the 4th quarter. DRW Securities LLC now owns 98,481 shares of the company’s stock worth $91,000 after purchasing an additional 29,336 shares during the last quarter. Finally, Adage Capital Partners GP L.L.C. increased its stake in Ensysce Biosciences by 100.4% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 149,711 shares of the company’s stock valued at $138,000 after purchasing an additional 75,000 shares in the last quarter. Institutional investors and hedge funds own 5.63% of the company’s stock.

About Ensysce Biosciences

Ensysce Biosciences, Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel prodrug therapies aimed at improving pain management and addressing opioid misuse. Leveraging its proprietary prodrug platform, the company designs drug candidates that convert into active pharmaceuticals through specific enzymatic action, providing controlled-release profiles and built-in abuse deterrence features.

The company’s lead product candidate, ENS100, is an investigational oral prodrug of hydrocodone engineered to reduce the potential for misuse and abuse compared to immediate-release opioid formulations.